Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • E-cigarettes significantly reduce tobacco cravings, study suggests

  • Coping strategies therapy significantly improves dementia carers' mental health, quality of life

  • Fathers' engagement with baby depends on mother

  • Unstable child care can affect children by age four

  • Self-regulation intervention boosts school readiness of at-risk children, study shows

  • Rejecting unsuitable suitors is easier said than done

  • Reported opioid abuse in pregnant women more than doubles in 14 years

  • Computerized cognitive training has modest benefits for cognitively healthy older adults

  • Gamification for behavior change: What is it and how is it useful?

  • Spatial memory: Orientation study suggests that a visual image of the intermediate spatial environment exists in brain

  •